THE CLINICAL COURSE OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OVER TIME: A MULTISTATE SURVIVAL ANALYSIS USING META-DATA FROM 13 FIRST-LINE RANDOMIZED TRIALS

Introduction: The Surrogate Endpoints for Aggressive Lymphoma (SEAL) collaboration established a meta-database integrating individual patient data from 13 first-line randomized clinical trials on previously untreated diffuse large B-cell lymphoma (DLBCL). This meta-database provides an opportunity to investigate the impact of clinical factors and treatment response on DLBCL-specific and other causes of death following initial therapy to define...